Polaryx Therapeutics ratios data for the quarter ended Jun 2026. These financial ratios cover 2 quarters of results from Mar 2026 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Mar2026 | Jun2026 |
|---|---|---|
| Efficiency | ||
| Assets AverageAssets Avg. | 4.34M | 7.66M |
| Valuation | ||
| Price to EarningsP/E | -140.69 | -96.08 |
| Price to BookP/B | 143.86 | 12.12 |
| Enterprise Value | 354.84M | 121.05M |
| EV to EBIT | -181.22 | -87.72 |
| EV to EBITDA | -181.22 | -87.72 |
| Market Capitalization | 357.92M | 132.59M |
| Price to FCFP/FCF | -170.44 | -99.54 |
| EV to FCF | -168.97 | -90.88 |
| EV to CFO | -168.97 | -90.88 |
| Return Ratios | ||
| Return on Capital Employed [ROCE]ROCE | -136.70% | |
| Return on Assets [ROA]ROA | -121.12% |